|By Business Wire||
|December 16, 2013 06:08 AM EST||
Precision Therapeutics announced today the publication of a feasibility study on the GeneFx® Colon microarray-based signature that supports the utilization of a new, automated method for extracting quality RNA. Previous validation efforts utilized a manual extraction process. This study was conducted in conjunction with Siemens Healthcare Diagnostics, Inc. using their Tissue Preparation Solution which includes an extraction platform and reagents. The abstract, titled, Comparison of Fully Automated and Manual Extraction Methods from Formalin-Fixed, Paraffin-Embedded Tissue for Use in a Prognostic Microarray-Based Genomic Signature, is included in the November issue of the Journal of Molecular Diagnostics.
“The automated method utilized by Precision would increase the accuracy and reproducibility of GeneFx Colon as well as standardize the workflow, reducing processing time, and increasing batch size,” said Laurie K. Huard, FACHE, Vice President of Operations at Precision Therapeutics. “This automation creates more dependable, precise results for patients and continues Precision’s commitment to improve and expound on current technology.”
About GeneFx® Colon
GeneFx® Colon is a gene expression-based, prognostic signature for stage II colon cancer that assesses a patient’s risk of recurrence within 5 years following surgery. Approximately 25 - 30% of colon cancer patients present with stage II disease, and approximately 20% of stage II patients will develop distant recurrence despite surgical “cure.” Clinical trials suggest less than 5% of stage II patients benefit from adjuvant chemotherapy, presenting the need to identify the subset of patients that are at high-risk for recurrence and candidates for adjuvant therapy.
About Colorectal Cancer
There are an estimated 1,154,481 people currently living with colorectal cancer in the United States with an estimated 142,820 new cases in 2013. Colorectal cancer is the second leading cause of cancer death in the United States. The earlier colorectal cancer is caught, the better the survival rate. Forty percent of patients are diagnosed at the local stage with a 5-year survival rate of 90.3%.1
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. For more information, visit: www.precisiontherapeutics.com or www.chemofx.com.
1 National Cancer Institute, http://seer.cancer.gov/statfacts/html/colorect.html